Idhifa Approved for Some With Acute Myeloid Leukemia

TUESDAY, Aug. 1, 2017 -- Idhifa (enasidenib) has been approved by the U.S. Food and Drug Administration to treat adults with a specific genetic mutation that leads to relapsed or refractory acute myeloid leukemia (AML). The mutation in the IDH2...
Source: Drugs.com - Daily MedNews - Category: General Medicine Source Type: news